Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bob Swift who wrote (3525)	7/31/1999 10:53:00 AM
From: BDR	Read Replies (1) of 10280

newspage.com WASHINGTON, July 28/PRNewswire/ via NewsEdge Corporation -- The Campaign for Fair Pharmaceutical Competition today launched campaigns in three states to stop passage of S. 1172, a bill in the U.S. Senate to extend the patent on the blockbuster allergy drug Claritin and seven other popular drugs. The campaigns will be directed against aggressive efforts by Senators Robert Torricelli (D-NJ), Jeff Sessions (R-AL), and Chuck Hagel (R-NE) to help Schering-Plough extend the patent on Claritin, which generates over $2 billion annually for the company. Under current law, the patent will expire in 2002, forcing the company to face competition. . . . So, if SGP is supposed to file a NDA for desloratadine by year end, should we care whether this bill to passes or fails?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next